Colchicine pharmacokinetics and mechanism of action

Current Pharmaceutical Design

Volumn 24, Issue 6, 2018, Pages 659-663

  Angelidis, Christos ^a   Kotsialou, Zoi ^a   Kossyvakis, Charalampos ^b   Vrettou, Agathi Rosa ^a   Zacharoulis, Achilleas ^a   Kolokathis, Fotios ^a   Kekeris, Vasilios ^b   Giannopoulos, Georgios ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b KAT HOSPITAL   (Greece)

Author keywords

Colchicine; Inflammation; Mechanism of action; Microtubules; Pharmacokinetics; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; CLARITHROMYCIN; COLCHICINE; CYCLOSPORINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ERYTHROMYCIN; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; L SELECTIN; MACROLIDE; MEVINOLIN; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; RHO KINASE; SIMVASTATIN; SUPEROXIDE; TOLBUTAMIDE; TUMOR NECROSIS FACTOR; ANTIGOUT AGENT; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A;

ACUTE KIDNEY FAILURE; ACUTE LIVER FAILURE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CARDIOVASCULAR DISEASE; CELL DIVISION; CELL MIGRATION; CELL TRANSPORT; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG STRUCTURE; DRUG WITHDRAWAL; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; HYPOVOLEMIA; MAXIMUM PLASMA CONCENTRATION; MICROTUBULE ASSEMBLY; NAUSEA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RESPIRATORY FAILURE; REVIEW; RHABDOMYOLYSIS; SEIZURE; SIGNAL TRANSDUCTION; VOMITING; DRUG EFFECT; METABOLISM; MICROTUBULE;

ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1; COLCHICINE; CYTOCHROME P-450 CYP3A; GOUT SUPPRESSANTS; HUMANS; MICROTUBULES;

EID: 85048855192     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612824666180123110042     Document Type: Review

References (43)

1. Hartung EF. History of the use of colchicum and related medicaments in gout; with suggestions for further research. Ann Rheum Dis 1954; 13: 190-200.
2. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 2012; 64: 1447-61.
3. Goldfinger SE. Colchicine for familial mediterranean fever. N Engl J Med 1972; 287: 1302.
4. Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 2001; 44: 2686-92.
5. Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. The task force for the diagnosis and management of pericardial diseases of the european society of cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015; 36: 2921-64.
6. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2017; 14: e275-e444.
7. Deftereos S, Giannopoulos G, Angelidis C, et al. Anti-inflammatory treatment with colchicine in acute myocardial infarction: A pilot study. Circulation 2015; 132: 1395-403.
8. Nidorf SM, Eikelboom JW, Thompson PL. Colchicine for secondary prevention of cardiovascular disease. Curr Atheroscler Rep 2014; 16: 391.
9. Ferron GM, Rochdi M, Jusko WJ, Scherrmann JM. Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. J Clin Pharmacol 1996; 36: 874-83.
10. Chappey ON, Niel E, Wautier JL, et al. Colchicine disposition in human leukocytes after single and multiple oral administration. Clin Pharmacol Ther 1993; 54: 360-7.
11. Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 2007; 12: 927-41.
12. Slobodnick A, Shah B, Pillinger MH, Krasnokutsky S. Colchicine: old and new. Am J Med 2015; 128: 461-70.
13. Ben-Chetrit E, Scherrmann JM, Zylber-Katz E, Levy M. Colchicine disposition in patients with familial Mediterranean fever with renal impairment. J Rheumatol 1994; 21: 710-3.
14. Solak Y, Atalay H, Biyik Z, et al. Colchicine toxicity in end-stage renal disease patients: a case-control study. Am J Ther 2014; 21: e189-95.
15. Wason S, Faulkner RD, Davis MW. Are dosing adjustments required for colchicine in the elderly compared with younger patients? Adv Ther 2012; 29: 551-61.
16. Roubille F, Kritikou E, Busseuil D, Barrere-Lemaire S, Tardif JC. Colchicine: an old wine in a new bottle? Antiinflamm Antiallergy Agents Med Chem 2013; 12: 14-23.
17. Mullins ME, Carrico EA, Horowitz BZ. Fatal cardiovascular collapse following acute colchicine ingestion. J Toxicol Clin Toxicol 2000; 38: 51-4.
18. Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M. Colchicine myopathy and neuropathy. N Engl J Med 1987; 316: 1562-8.
19. Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum 2009; 38: 411-9.
20. Hastie SB. Interactions of colchicine with tubulin. Pharmacol Ther 1991; 51: 377-401.
21. Nogales E, Whittaker M, Milligan RA, Downing KH. High-resolution model of the microtubule. Cell 1999; 96: 79-88.
22. Nogales E. Structural insight into microtubule function. Annu Rev Biophys Biomol Struct 2001; 30: 397-420.
23. Bhattacharyya B, Panda D, Gupta S, Banerjee M. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med Res Rev 2008; 28: 155-83.
24. Howard J, Hyman AA. Dynamics and mechanics of the microtubule plus end. Nature 2003; 422: 753-8.
25. Panda D, Miller HP, Wilson L. Rapid treadmilling of brain microtubules free of microtubule-associated proteins in vitro and its suppression by tau. Proc Natl Acad Sci USA 1999; 96: 12459-64.
26. Panda D, Miller HP, Wilson L. Determination of the size and chemical nature of the stabilizing "cap" at microtubule ends using modulators of polymerization dynamics. Biochemistry 2002; 41: 1609-17.
27. Cassimeris L. Accessory protein regulation of microtubule dynamics throughout the cell cycle. Curr Opin Cell Biol 1999; 11: 134-41.
28. Downing KH. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu Rev Cell Dev Biol 2000; 16: 89-111.
29. Ravelli RB, Gigant B, Curmi PA, et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004; 428: 198-202.
30. Taylor EW. The mechanism of colchicine inhibition of mitosis. I. Kinetics of inhibition and the binding of H3-Colchicine. J Cell Biol 1965; 25: 145-60.
31. Fankhauser G, Humphrey RR. The rare occurrence of mitosis without spindle apparatus ("Colchicine Mitosis") Producing endo-polyploidy in embryos of the axolotl. Proc Natl Acad Sci USA 1952; 38: 1073-82.
32. Cronstein BN, Molad Y, Reibman J, Balakhane E, Levin RI, Weissmann G. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995; 96: 994-1002.
33. Leung YY, Hui LLY, Kraus VB. Colchicine---update on mechanisms of action and therapeutic uses. Seminars Arthritis Rheumatism 2015; 45: 341-50.
34. Shah B, Allen N, Harchandani B, et al. Effect of colchicine on platelet-platelet and platelet-leukocyte interactions: a pilot study in healthy subjects. Inflammation 2016; 39: 182-9.
35. Chia EW, Grainger R, Harper JL. Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: a rationale for use of low-dose colchicine. Br J Pharmacol 2008; 153: 1288-95.
36. Mariathasan S, Newton K, Monack DM, et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 2004; 430: 213-8.
37. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-41.
38. Misawa T, Takahama M, Kozaki T, et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol 2013; 14: 454-60.
39. Martinez GJ, Robertson S, Barraclough J, et al. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J Am Heart Assoc 2015; 4: e002128.
40. Marques-da-Silva C, Chaves MM, Castro NG, Coutinho-Silva R, Guimaraes MZ. Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor-expressing cells: implications for its therapeutic action. Br J Pharmacol 2011; 163: 912-26.
41. Takenouchi T, Iwamaru Y, Sugama S, Sato M, Hashimoto M, Kitani H. Lysophospholipids and ATP mutually suppress maturation and release of IL-1 beta in mouse microglial cells using a Rho-dependent pathway. J Immunol 2008; 180: 7827-39.
42. Ding AH, Porteu F, Sanchez E, Nathan CF. Downregulation of tumor necrosis factor receptors on macrophages and endothelial cells by microtubule depolymerizing agents. J Exp Med 1990; 171: 715-27.
43. Jackman RW, Rhoads MG, Cornwell E, Kandarian SC. Microtubule-mediated NF-kappaB activation in the TNF-alpha signaling pathway. Exp Cell Res 2009; 315: 3242-9.